Vaxcell-Bio, a Korean biotech company specializing in immunotherapy, said it will officially launch Vaxlukin-15, Korea’s first pet immunotherapy, in late March.
Vaxcell-Bio is set to launch Korea’s first pet immunotherapy, Vaxlukin-15, in April, targeting canine cancers with plans for global expansion. The picture shows a dog receiving Vaxlukin-15 at a veterinary hospital. (Credit: Vaxcell-Bio)
Vaxcell-Bio is set to launch Korea’s first pet immunotherapy, Vaxlukin-15, in April, targeting canine cancers with plans for global expansion. The picture shows a dog receiving Vaxlukin-15 at a veterinary hospital. (Credit: Vaxcell-Bio)
The company recently supplied the initial batch of Vaxlukin-15 to Yuhan Corp., which will distribute the drug nationwide through veterinary pharmaceutical dealers starting in late March. As a result, veterinarians will be able to prescribe and administer the drug starting in April.
Vaxlukin-15 demonstrated significant clinical benefits in a trial involving dogs that had undergone mammary tumor resection. The study showed that dogs treated with Vaxlukin-15 experienced improved clinical symptoms and quality of life compared to the control group, which received only surgery. Also, the drug exhibited minimal side effects and was confirmed to be safe through physical and hematological examinations.
At the upcoming 2025 Seoul Veterinary Spring Clinical Conference on March 29-30, Vaxcell-Bio will present data on Vaxlukin-15’s immunotherapy effects, while Yuhan Corporation will operate a promotional booth to initiate full-scale marketing efforts.
The company is also seeking to expand the drug’s indications beyond canine mammary tumors to include lymphoma, and eventually feline cancers. Vaxcell-Bio has already completed clinical trials confirming the drug’s efficacy and safety for canine lymphoma and has submitted a marketing authorization application to the Animal and Plant Quarantine Agency.
“Aside from broadening Vaxlukin-15’s indications across various cancer types, we are pursuing patent applications for novel administration routes to enhance convenience,” Vaxcell-Bio CEO Lee Je-jung said. “We are also developing continent-specific export strategies to bring Vaxlukin-15 to the global market.”
Related articles
Yuhan to co-promote VaxCell-Bio’s pet immunotherapy
Love and heartache: Pet owners struggle with high veterinary costs and aging pets
Lee Han-soo corea022@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited